Analyst Ratings for Moderna (MRNA)
MRNA Rating Summary
MRNA Price Target Summary
- Highest: $231.00 (Piper Sandler)
- Lowest: $68.00 (Roth Capital)
- Average: $153.29
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$153.29 (-6%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 50%
Avg. $ Target:
$153.29 (-6%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 50%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/1/2021 | BofA Securities | Geoff Meacham | Downgrade | Underperform (Neutral) |
N/A (N/A) |
173.16 (163.15) |
-5.78% | Details |
| 12/16/2020 | Morgan Stanley » Updated 5/6/2021 |
Matthew Harrison | Downgrade | Equalweight (Overweight) |
201.00 (N/A) |
155.07 (163.15) |
5.21% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
MRNA Ratings News
- Pfizer (PFE) Down on Potential IP Wavers, Mizuho Downgrades to 'Neutral' as it Sees No Clear Drivers of Meaningful Upside
- Moderna (MRNA) PhII Booster Data Demonstrates Protection Against South African and Brazilian Variants - Morgan Stanley
- Moderna (MRNA) Announces 500M Dose Vaccine Supply Agreement with Gavi for Lowest Income Countries, Analyst Bullish
- See More
